Carisma Therapeutics, Inc. (CARM)
CARM moved a median of -0.70% 30 minutes after news, and -1.14% by the close. How CARM actually reacts to news — the realized, point-in-time move the market made, measured across 147 labeled events over the last three years with zero look-ahead.
CARM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.04% | 42% | 147 |
| 30-min | -0.70% | 40% | 147 |
| 60-min | -0.60% | 42% | 147 |
| to close | -1.14% | 40% | 146 |
| Middle 50% of CARM reactions | -2.96% to +1.86% |
|---|---|
| Median reaction (30-min) | -0.70% |
| Measured reactions | 147 |
Half of all Carisma Therapeutics, Inc. news events land between -2.96% and +1.86% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CARM reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 11 | -7.29% | 27% | -9.72% |
| Rating reiterations | 23 | -0.36% | 30% | -2.53% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how CARM ranks against every other measured name →
That’s how CARM usually reacts — get an email when it moves on news →Email me when CARM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CARM's baseline. Nothing else.
Recent CARM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Carisma Therapeutics | SEC filing · Form 15-12G | SEC EDGAR | +6.73% | -0.23% | |
| Form EFFECT Carisma Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | +4.75% | +2.91% | |
| Form 25 Carisma Therapeutics | SEC filing · Form 25 | SEC EDGAR | -0.21% | +5.46% | |
| Form POS AM Carisma Therapeutics | SEC filing · Form POS | SEC EDGAR | -0.21% | +5.46% | |
| Form S-8 POS Carisma Therapeutics | SEC filing · Form S-8 | SEC EDGAR | -0.21% | +5.46% | |
| Carisma Announces Delisting from Nasdaq and SEC Deregistration | Press release | PR Newswire | +4.00% | +6.00% | |
| Form 8-K Carisma Therapeutics For: Dec 04 | SEC filing · Form 8-K | SEC EDGAR | -14.54% | -10.54% | |
| Form 10-Q Carisma Therapeutics For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +12.83% | — | |
| Form 8-K Carisma Therapeutics For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | -1.32% | +11.91% | |
| Form 8-K Carisma Therapeutics For: Oct 09 | SEC filing · Form 8-K | SEC EDGAR | -4.92% | -3.02% | |
| Form 8-K Carisma Therapeutics For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | +3.42% | -11.29% | |
| Form RW Carisma Therapeutics | SEC filing · Form RW | SEC EDGAR | +3.42% | -11.29% | |
| Form 8-K Carisma Therapeutics For: Aug 29 | SEC filing · Form 8-K | SEC EDGAR | -7.01% | -18.88% | |
| Form S-4/A Carisma Therapeutics | SEC filing · Form S-4 | SEC EDGAR | -7.01% | -18.88% | |
| Form 8-K Carisma Therapeutics For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.04% | |
| Form 10-Q Carisma Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.29% | -2.53% | |
| Form DEFA14A Carisma Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | -1.85% | -2.42% | |
| Form S-4 Carisma Therapeutics | SEC filing · Form S-4 | SEC EDGAR | +2.56% | -0.05% | |
| Form 8-K Carisma Therapeutics For: Jul 09 | SEC filing · Form 8-K | SEC EDGAR | +1.21% | -0.25% | |
| Form DEF 14A Carisma Therapeutics For: Aug 05 | SEC filing · Form DEF | SEC EDGAR | -2.54% | +3.08% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX) | Press release | GlobeNewswire | -0.95% | -4.39% | |
| Form PRE 14A Carisma Therapeutics For: Jun 27 | SEC filing · Form PRE | SEC EDGAR | -0.02% | -6.76% | |
| CARM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Carisma Therapeutics Inc. Is Fair to Shareholders | Press release | Business Wire | +0.56% | +5.50% | |
| Form 8-K Carisma Therapeutics For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +1.19% | +1.33% | |
| Form 8-K Carisma Therapeutics For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +0.82% | -3.83% | |
| Form 10-Q Carisma Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.32% | +1.53% | |
| Form 10-K/A Carisma Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.01% | +0.81% | |
| Form 8-K Carisma Therapeutics For: Apr 10 | SEC filing · Form 8-K | SEC EDGAR | -1.13% | -1.13% | |
| Carisma Therapeutics Provides Corporate Updates | Press release | PR Newswire | -10.40% | -23.17% | |
| Form 10-K Carisma Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -10.40% | -23.17% | |
| Form S-8 Carisma Therapeutics | SEC filing · Form S-8 | SEC EDGAR | -10.40% | -23.17% | |
| Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference | Press release | PR Newswire | +2.23% | +2.08% | |
| Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference | Press release | PR Newswire | +2.39% | +16.05% | |
| Form 8-K Carisma Therapeutics For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | -0.86% | -3.52% | |
| Form 8-K Carisma Therapeutics For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | -0.86% | -3.52% | |
| Form 8-K Carisma Therapeutics For: Dec 24 | SEC filing · Form 8-K | SEC EDGAR | +1.23% | +2.29% | |
| Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline | Press release | PR Newswire | -2.02% | -4.27% | |
| Form 8-K Carisma Therapeutics For: Dec 07 | SEC filing · Form 8-K | SEC EDGAR | -2.02% | -4.27% | |
| Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference | Press release | PR Newswire | +0.00% | -1.06% | |
| Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024 | Press release | PR Newswire | -0.55% | -3.31% | |
| Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma | Press release | PR Newswire | -3.83% | -2.88% | |
| Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Press release | PR Newswire | -0.46% | -4.63% | |
| Form 10-Q Carisma Therapeutics For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.46% | -4.63% | |
| Form 8-K Carisma Therapeutics For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | -0.46% | -4.63% | |
| Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024 | Press release | PR Newswire | -1.40% | +2.80% | |
| Carisma Therapeutics Announces Changes to its Board of Directors | Press release | PR Newswire | +0.00% | -1.67% | |
| Form 8-K Carisma Therapeutics For: Oct 24 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.67% | |
| Form 8-K Carisma Therapeutics For: Oct 10 | SEC filing · Form 8-K | SEC EDGAR | -0.01% | +0.56% | |
| Carisma Therapeutics Announces Upcoming Presentations at SITC 2024 | Press release | PR Newswire | -0.57% | +0.49% | |
| Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases | Press release | PR Newswire | -4.84% | -3.98% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CARM section they belong to.
Where else CARM is measured.
CARM earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Carisma Therapeutics, Inc.'s median reaction calculated?
Every labeled CARM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 147 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of CARM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CARM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.